Liquidia Technologies Inc (LQDA)
Liquidia Technologies Inc. is a biopharmaceutical company listed on the NASDAQ under the ticker LQDA. The company focuses on therapies for rare cardiopulmonary diseases in the United States. Its pipeline includes YUTREPIA, an inhaled dry powder version of treprostinil being developed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also markets Remodulin, a treprostinil injection delivered by continuous intravenous or subcutaneous infusion, and is advancing L606, an investigational liposomal treprostinil formulation in phase III testing for the same disease areas. In addition, the company develops PRINT technology, which is designed to create uniform drug particles with controlled size, shape, and composition. Liquidia was founded in 2004 and is based in Morrisville, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LQDA
|
$48.81
|
9.7% Upside
|
Fair
|
$54.38
|
22.2% Upside
|
Undervalued
|
Great
|
0.0%
|
28.7x
|
20.4x
|
8.8x
|
3.982 B
|
3.881 B
|
4.4%
|
72.9%
|
8.5
|
108.7%
|
